206-838-5110 ext. 102 general@etubics.com
messerSEATTLE – (July 9, 2015) –

Etubics Corporation, a privately-held, clinical stage biotechnology company developing an immunotherapy vaccine platform, announced today that it has retained Gerald L. Messerschmidt, MD, FACP as Chief Medical Officer. The company is currently in development of the Etubics Platform with the National Cancer Institute, which will employ novel immunotherapeutic cancer treatments in preclinical and clinical trials.

“Dr. Messerschmidt’s vast experience in product development at both large and start-up companies will be invaluable to Etubics’ goal to bring a multi-targeted immunotherapeutic cancer treatment to the market,” said Dr. Frank Jones, the founder, Chairman and CEO of Etubics Corporation. “His knowledge of the industry will help guide Etubics through successful trials of our breakthrough immunotherapy vaccines, a promising alternative to the current cancer treatments available.”

Bringing nearly 35 years of experience in clinical oncology and gene therapy, Messerschmidt will advise and oversee ongoing clinical trials and the development of the Etubics Platform for multiple cancer indications. He has served as chairman and CEO of Wild-Type Enterprises Worldwide, LLC, an oncology drug and device development consulting firm. Prior, Messerschmidt was the vice president (VP) of oncology for worldwide clinical trials and VP of global clinical research and development for Talon Therapeutics where he worked on the FDA approval of the drug Marqibo. Previously he assisted ONYX Pharmaceuticals where he led the development of three novel drugs. In addition, Dr. Messerschmidt was head of the Laboratory of Experimental Hematology at the National Institutes of Health and a Major in the United States Air Force where he was an oncology and hematology consultant to the Surgeon General. He has also been awarded the Pennsylvania State “Medal of Honor” by The State of Pennsylvania House of Representatives.

Dr. Messerschmidt

“I am thrilled to work with Etubics,” said Dr. Messerschmidt. “This company is building the future of cancer treatment, developing vaccines that work with the human body to fight some of the hardest to treat cancers. It is an exciting time to be in the industry.”

Dr. Messerschmidt earned a B.S. in Biology from Portland State University, and a M.D. from the University of Oregon School of Medicine.

About Etubics Corporation 

Etubics Corporation, based in Seattle, Wash., is a third generation clinical stage bio-pharmaceutical company developing a proprietary gene delivery platform technology consisting of a genetically engineered adenovirus vector delivery system and a manufacturing E.C7 human cell line, collectively the Etubics Platform. Phase 1 and 2 clinical trials to date show that the Etubics Platform overcomes challenges associated with all other viruses including prior generation adenoviruses. The Company’s gene delivery platform can be used to efficiently and rapidly develop immunotherapeutic drugs and preventive vaccines for a wide range of cancers, infectious diseases and other chronic illnesses associated with genetic abortions.

Forward look statements:

Statements herein relating to future financial, business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Etubics is a private company. Etubics cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including the failure by Etubics to secure and maintain relationships with collaborators; risks relating to the early state of Etubics’s product candidates under development; uncertainties relating to clinical trials and regulatory requirements and actions; risks relating to the commercialization, if any, of Etubics proposed product candidates; competitive risks to marketed products; dependence on the efforts of third parties; dependence on intellectual property; and risks that it may lack the financial resources and access to capital to fund its operations. Further information on the factors and risks that could affect Etubics’s offices, business, financial conditions and results of operations, are contained in Etubics’s documents on file at the Company. These forward-looking statements speak only as of the date of this press release and Etubics assumes no duty to update forward-looking statements.

Media Contacts           

Kimberly French / Jason Hamilton

Richmond Public Relations / 206-682-6979

Kimberlyf@richmondpr.comjasonh@richmondpr.com